News & Events
4th Annual Evercore ISI HealthCONx Conference
Event Date: December 2, 2021
READ MORECrinetics Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference
Crinetics Pharmaceuticals ($CRNX) announced today that company management will participate in a fireside chat and one-on-one investor meetings at the...
READ MORECrinetics Pharmaceuticals Presenting New Data from Open Label Extension Trial of Paltusotine in Acromegaly at the Society for Endocrinology BES Congress
Crinetics Pharmaceuticals ($CRNX) announced today that new data from ACROBAT Advance, the ongoing open label extension (OLE) trial of paltusotine...
READ MORECrinetics Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
We also continue to make strong progress in our efforts to develop paltusotine as an oral treatment for acromegaly and...
READ MORECrinetics Pharmaceuticals Announces Closing of Public Offering of Common Stock
Crinetics Pharmaceuticals ($CRNX) has closed its previously announced underwritten public offering of 8,712,400 shares of its common stock, including 1,136,400...
READ MORECrinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Crinetics intends to use the net proceeds from the offering to fund the development of paltusotine, CRN04894, CRN04777 and its...
READ MORECrinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
Crinetics announced today that it intends to offer and sell, subject to market and other conditions, shares of its common...
READ MORERadionetics Oncology Emerges from Crinetics Pharmaceuticals with a Platform and Deep Pipeline of Nonpeptide Targeted Radiopharmaceutical Drug Candidates for Precision Oncology
Radionetics’ pipeline is based on a broadly enabling platform and intellectual property that will leverage more than a decade of...
READ MORECrinetics Pharmaceuticals Unveils Parathyroid Hormone Receptor Antagonist Program at ASBMR
“Our PTHR1 antagonists have the potential to improve the lives of people with hypercalcemia caused by parathyroid adenomas; and moreover,...
READ MORECRN04777 Demonstrates Pharmacologic Proof-of-Concept with Strong Dose-dependent Suppression of Insulin Secretion in Phase 1 Single Ascending Dose Study
Alan Krasner, M.D., chief medical officer at Crinetics, added, “We are very encouraged by these single ascending dose data that...
READ MORETransforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.